Keros Therapeutics, Inc.

Report azionario NasdaqGM:KROS

Capitalizzazione di mercato: US$221.5m

Keros Therapeutics Performance degli utili passati

Criteri Il passato verificati 0/6

Keros Therapeutics ha registrato una crescita degli utili a un tasso medio annuo di 8.7%, mentre il settore Biotechs ha registrato utili in crescita a un tasso medio annuo di 33.8%. I ricavi sono stati in crescita a un tasso medio annuo di 72.2%.

Informazioni chiave

8.66%

Tasso di crescita degli utili

14.22%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.04%
Tasso di crescita dei ricavi72.23%
Rendimento del capitale proprio-29.81%
Margine netto-256.60%
Ultimo aggiornamento sugli utili31 Mar 2026

Aggiornamenti sulle prestazioni recenti

Articolo di analisi • May 14

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

Investors were underwhelmed by the solid earnings posted by Keros Therapeutics, Inc. ( NASDAQ:KROS ) recently. We did...

Recent updates

Articolo di analisi • Nov 18

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Keros Therapeutics, Inc. ( NASDAQ:KROS ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • Aug 21

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

Summary Keros Therapeutics, Inc. faces uncertainty after discontinuing its lead asset, with current value driven mainly by a strong cash position and pipeline potential. KER-065 received FDA Orphan Drug designation for Duchenne Muscular Dystrophy, but efficacy and approval remain years away and unproven. Elritercept, now partnered with Takeda, offers milestone and royalty potential, but faces tough competition and uncertain commercial prospects. Given limited near-term catalysts and high risk, I maintain a Hold rating—Keros is interesting, but KROS stock lacks enough data for a bullish stance. Read the full article on Seeking Alpha
Articolo di analisi • May 29

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

Key Insights Keros Therapeutics to hold its Annual General Meeting on 4th of June Salary of US$699.0k is part of CEO...
Articolo di analisi • May 14

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

Investors were underwhelmed by the solid earnings posted by Keros Therapeutics, Inc. ( NASDAQ:KROS ) recently. We did...
Articolo di analisi • May 09

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

Keros Therapeutics, Inc. ( NASDAQ:KROS ) shares have had a really impressive month, gaining 44% after a shaky period...
Seeking Alpha • Mar 13

Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine

Summary Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Despite a strong cash position and a Takeda partnership elsewhere, the future of Keros' lead candidate, Cibotercept, appears bleak. The company has a cash runway of 13 quarters, but high short interest and low trading volume pose additional risks. Given the current situation, I recommend avoiding KROS, although risk-loving investors might find its low price and cash reserves appealing. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff

Summary Keros Therapeutics, Inc.'s stock plummeted over 75% due to halting high-dose arms in its Phase 2 TROPOS trial for PAH, citing safety concerns. Despite the setback, Keros' partnership with Takeda Pharmaceutical Company for elritercept and its potential $900m annual revenue offers a safety net. The market reaction may be too harsh; past biotech clinical study setbacks have often been resolved, presenting a contrarian investment opportunity. Investors should wait for more data on cibotercept's safety issues before making definitive judgments. Read the full article on Seeking Alpha
Articolo di analisi • Nov 20

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Aug 07

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jun 10

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Summary Five Keros Therapeutics, Inc. abstracts are expected at the upcoming EHA conference between June 13th -16th of 2024, showcasing data using KER-050 for the treatment of patients with low-risk myelodysplastic syndrome. The company has already met with the FDA and agreed on a design for a phase 3 study using KER-050 for the treatment of low-risk MDS. The global myelodysplastic syndrome market is projected to reach $6.10 billion by 2029. Keros Therapeutics is also developing the use of KER-050 for the treatment of patients with myelofibrosis and data from the phase 2 study for this program is expected in Q4 2024. Read the full article on Seeking Alpha
Articolo di analisi • Apr 23

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Key Insights The projected fair value for Keros Therapeutics is US$94.52 based on 2 Stage Free Cash Flow to Equity...
Articolo di analisi • Sep 24

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Jun 10

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Articolo di analisi • Sep 08

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 04

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Keros Therapeutics press release (NASDAQ:KROS): Q2 GAAP EPS of -$1.13 misses by $0.07. Cash and cash equivalents OF $215.62M
Articolo di analisi • Apr 29

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Jan 24

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Oct 10

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • May 05

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Ripartizione dei ricavi e delle spese

Come Keros Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storico di utili e ricavi

NasdaqGM:KROS Ricavi, spese e utili (USD Millions )
DataRicaviUtiliSpese G+ASpese di R&S
31 Mar 2633-85460
31 Dec 2524487460
30 Sep 2524764450
30 Jun 2523319450
31 Mar 252154410
31 Dec 244-187410
30 Sep 241-182390
30 Jun 240-168390
31 Mar 240-160370
31 Dec 230-153350
30 Sep 230-142330
30 Jun 230-127310
31 Mar 230-116290
31 Dec 220-105280
30 Sep 2220-82260
30 Jun 2220-79250
31 Mar 2220-67230
31 Dec 2120-59210
30 Sep 210-61190
30 Jun 210-53170
31 Mar 210-49150
31 Dec 200-45130
30 Sep 203-39100
30 Jun 205-3180
31 Mar 208-2350
31 Dec 1910-1430
31 Dec 1810-220

Guadagni di qualità: KROS al momento non è redditizia.

Margine di profitto in crescita: KROS al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: KROS non è redditizia, ma ha ridotto le perdite negli ultimi 5 anni a un tasso pari a 8.7% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di KROS nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: KROS non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 43% ).

Rendimento del capitale proprio

ROE elevato: KROS ha un Return on Equity negativo ( -29.81% ), in quanto al momento non è redditizio.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/26 21:49
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Keros Therapeutics, Inc. è coperta da 17 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jason ZemanskyBofA Global Research
Corinne JohnsonGoldman Sachs
Andrew FeinH.C. Wainwright & Co.